Paper Details

  1. Home
  2. Paper Details

Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.

Author: AdenisJ P, BadrinathS S, CaldwellD R, EifermanR A, HyndiukR A, KatzH R, KlaussV, ReddyM K, RosenwasserG O, SantosC I

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Topical ciprofloxacin monotherapy is equivalent clinically and statistically to the standard therapy regimen of fortified antibiotics for the treatment of bacterial corneal ulcers and produces significantly less discomfort.
Paper Details　
Original Abstract of the Article :
PURPOSE: The purpose of the study is to compare the clinical efficacy and safety of ciprofloxacin ophthalmic solution 0.3% (Ciloxan) with a standard therapy regimen (fortified tobramycin, 1.3%-cefazolin, 5.0%) for treating bacterial corneal ulcers. METHODS: This randomized, parallel group, double-m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0161-6420(96)30416-8

データ提供：米国国立医学図書館（NLM）

Ciprofloxacin vs. Fortified Tobramycin-Cefazolin: A Battle for the Eyes

Bacterial corneal ulcers are a serious threat to vision. This research compares the effectiveness of ciprofloxacin ophthalmic solution 0.3% to a standard therapy regimen of fortified tobramycin-cefazolin in treating these ulcers. It's like comparing two different swords in a battle for the eyes, seeking the sharpest and most effective weapon against infection.

The researchers conducted a double-blind, multicenter study on 324 patients with bacterial corneal ulcers. They compared the effectiveness of the two treatments, focusing on healing time, pain relief, and overall success. This research is like observing two different armies fighting for control of a strategic desert outpost – comparing the effectiveness of different treatment approaches.

A Clear Winner in the Battle for Vision

The researchers found that ciprofloxacin monotherapy was as effective as the standard therapy regimen in treating bacterial corneal ulcers. However, ciprofloxacin caused significantly less discomfort for patients. It's like discovering a new weapon that is just as powerful but much easier to wield.

A Brighter Outlook for Eye Health

This research offers a promising new option for treating bacterial corneal ulcers. Ciprofloxacin monotherapy provides an effective and more comfortable treatment option for patients. It's like finding a wellspring of relief in the desert, offering a brighter future for those suffering from vision-threatening infections.

Dr.Camel's Conclusion

This study highlights the effectiveness of ciprofloxacin monotherapy in treating bacterial corneal ulcers. It's like finding a powerful and comfortable oasis in the desert of eye health. The results suggest that ciprofloxacin monotherapy is a valuable addition to the treatment options for bacterial corneal ulcers, offering a more comfortable and effective path to recovery.

Date :
  1. Date Completed 1996-12-20
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

8942881

DOI: Digital Object Identifier

10.1016/s0161-6420(96)30416-8

Related Literature

Article Analysis
・Effects of ciprofloxacin ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.